Innate Pharma Presents Positive Phase 1 Clinical Data for IPH4502 in Advanced Solid Tumors
Trendline

Innate Pharma Presents Positive Phase 1 Clinical Data for IPH4502 in Advanced Solid Tumors

What's Happening? Innate Pharma SA has announced encouraging initial Phase 1 clinical data for its investigational Nectin-4-targeting antibody-drug conjugate (ADC), IPH4502, in patients with advanced solid tumors. The results were presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets a
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.